ETF Holdings Breakdown of IONS

IONS institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	77,612	USD 5,672,661
2025-10-17	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	100,944	USD 7,377,997
2025-10-17	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	100,944	USD 7,377,997
2025-10-17	IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF)	2,276	USD 166,353
2025-10-17	IE000D8XC064 (iShares World Equity Enhanced Active UCITS ETF USD (Acc))	6,945	USD 507,610
2025-10-17	IE0009VWHAE6 (iShares US Equity Enhanced Active UCITS ETF USD (Acc))	19,320	USD 1,412,099
2025-10-17	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	105,818	USD 7,734,238 1.0%
2025-10-17	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	3,639	USD 265,975 1.0%
2025-10-17	IE000KJPDY61 (iShares World Equity High Income UCITS ETF USD Inc)	884	USD 64,612 0.0%
Total =		418,382	USD 30,579,542

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with IONS

Ionis Pharma Reports Positive Topline Results From Pivotal Study Of Zilganersen In Alexander Disease

(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) announced Monday positive topline results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying - 2025-09-22 08:36:13

Ionis Pharmaceuticals And Sobi Say EU Approves TRYNGOLZA For Familial Chylomicronemia Syndrome

(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) and Swedish biopharmaceutical company Sobi announced Friday that TRYNGOLZA (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicr - 2025-09-19 08:39:56

Citigroup Increases Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $84.00

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) had its target price boosted by equities research analysts at Citigroup from $69.00 to $84.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price target points to a potential upside of 41.53% from the stock’s previous close. A […] - 2025-09-05 05:03:17

IONS Crosses Above Average Analyst Target

In recent trading, shares of Ionis Pharmaceuticals Inc (Symbol: IONS) have crossed above the average analyst 12-month target price of $59.91, changing hands for $60.49/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgra - 2025-09-04 08:06:06

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price Expected to Rise, HC Wainwright Analyst Says

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) had its price target hoisted by investment analysts at HC Wainwright from $70.00 to $95.00 in a research note issued on Tuesday, MarketBeat Ratings reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 57.05% from the […] - 2025-09-04 04:34:50

Ionis Pharmaceuticals (NASDAQ:IONS) Sees Strong Trading Volume on Analyst Upgrade

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) saw strong trading volume on Wednesday after Citigroup raised their price target on the stock from $69.00 to $84.00. Citigroup currently has a buy rating on the stock. 1,757,603 shares changed hands during trading, a decline of 5% from the previous session’s volume of 1,844,968 […] - 2025-09-04 02:20:48

Stock Traders Buy High Volume of Call Options on Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 2,862 call options on the stock. Thisisanincreaseofapproximately218% compared to the average volume of 899 call options. Ionis Pharmaceuticals Stock Down 0.3% Shares of IONS opened at $42.62 on Friday. The firm has a […] - 2025-08-29 02:34:43

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $49.00 at JPMorgan Chase & Co.

Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) had its price target boosted by JPMorgan Chase & Co. from $48.00 to $49.00 in a research report report published on Monday morning,Benzinga reports. They currently have a neutral rating on the stock. A number of other equities research analysts also recently weighed in on the stock. Needham & […] - 2025-08-26 03:10:58

Citigroup Increases Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $69.00

Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) had its price objective upped by Citigroup from $65.00 to $69.00 in a report released on Friday morning,Benzinga reports. Citigroup currently has a buy rating on the stock. A number of other equities analysts also recently commented on IONS. HC Wainwright raised their price objective on Ionis Pharmaceuticals from […] - 2025-08-25 05:00:49

Barclays Forecasts Strong Price Appreciation for Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) had its price objective upped by Barclays from $57.00 to $58.00 in a research report report published on Friday morning,Benzinga reports. They currently have an overweight rating on the stock. Several other research firms have also recently weighed in on IONS. JPMorgan Chase & Co. increased their price target […] - 2025-08-25 02:58:58

HC Wainwright Raises Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $70.00

Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) had its price objective lifted by HC Wainwright from $65.00 to $70.00 in a report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock. Other analysts also recently issued research reports about the stock. Guggenheim reduced their price target on shares of Ionis Pharmaceuticals […] - 2025-08-25 02:58:55

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by Wall Street Zen

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday. A number of other analysts have also issued reports on IONS. Barclays raised Ionis Pharmaceuticals from an “equal weight” rating […] - 2025-08-18 04:37:05

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Swiss National Bank

Swiss National Bank decreased its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 1.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 275,300 shares of the company’s stock after selling 3,900 shares during the period. Swiss National Bank’s […] - 2025-08-17 05:21:00

Vanguard Group Inc. Sells 88,605 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Vanguard Group Inc. decreased its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 0.5% in the first quarter, Holdings Channel reports. The fund owned 16,383,934 shares of the company’s stock after selling 88,605 shares during the quarter. Vanguard Group Inc. owned approximately 0.10% of Ionis Pharmaceuticals worth $494,303,000 at the end of the […] - 2025-08-15 05:40:54

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 8.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,135 shares of the company’s stock after acquiring an additional 481 shares during the […] - 2025-08-15 04:47:02

Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up on Strong Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) shares gapped up prior to trading on Wednesday after the company announced better than expected quarterly earnings. The stock had previously closed at $41.48, but opened at $44.97. Ionis Pharmaceuticals shares last traded at $43.71, with a volume of 994,321 shares traded. The company reported $0.70 earnings […] - 2025-08-01 02:07:11

Signaturefd LLC Purchases 433 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Signaturefd LLC lifted its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 45.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,382 shares of the company’s stock after acquiring an additional 433 shares during the quarter. Signaturefd LLC’s […] - 2025-07-24 05:00:47

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stake Boosted by Xponance Inc.

Xponance Inc. boosted its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 5.1% in the first quarter, Holdings Channel reports. The fund owned 20,319 shares of the company’s stock after acquiring an additional 980 shares during the period. Xponance Inc.’s holdings in Ionis Pharmaceuticals were worth $613,000 as of its most […] - 2025-07-18 04:58:53

Brown Advisory Inc. Sells 704 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Brown Advisory Inc. cut its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 5.5% during the 1st quarter, HoldingsChannel reports. The firm owned 12,026 shares of the company’s stock after selling 704 shares during the period. Brown Advisory Inc.’s holdings in Ionis Pharmaceuticals were worth $363,000 at the end of the […] - 2025-07-16 04:58:50

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Acquired by Fifth Third Bancorp

Fifth Third Bancorp raised its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 4.8% in the 1st quarter, HoldingsChannel reports. The fund owned 9,989 shares of the company’s stock after buying an additional 458 shares during the quarter. Fifth Third Bancorp’s holdings in Ionis Pharmaceuticals were worth $301,000 as of its […] - 2025-06-19 04:55:02

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio decreased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 5.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 53,748 shares of the company’s stock after selling 3,077 shares during the period. Public Employees Retirement […] - 2025-06-02 05:38:55

Tidal Investments LLC Has $609,000 Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Tidal Investments LLC decreased its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 7.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,407 shares of the company’s stock after selling 1,501 shares during the period. Tidal Investments […] - 2025-05-28 06:30:50

Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up on Better-Than-Expected Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report)’s stock price gapped up prior to trading on Wednesday following a stronger than expected earnings report. The stock had previously closed at $29.81, but opened at $31.78. Ionis Pharmaceuticals shares last traded at $30.09, with a volume of 185,687 shares trading hands. The company reported ($0.93) EPS […] - 2025-05-02 02:10:54

Mariner LLC Has $967,000 Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Mariner LLC raised its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 19.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 27,661 shares of the company’s stock after acquiring an additional 4,534 shares during the quarter. Mariner LLC’s holdings in […] - 2025-04-28 05:46:51

Raymond James Financial Inc. Purchases Shares of 105,619 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Raymond James Financial Inc. purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 105,619 shares of the company’s stock, valued at approximately $3,692,000. Raymond James Financial Inc. owned about 0.07% of Ionis Pharmaceuticals […] - 2025-04-28 05:46:49

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. cut its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 10.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 52,688 shares of the company’s stock after selling 6,126 shares during the period. […] - 2025-04-28 04:37:03

Ionis Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) was the target of some unusual options trading on Monday. Stock traders bought 5,610 call options on the company. This is an increase of approximately 1,252% compared to the typical volume of 415 call options. Wall Street Analysts Forecast Growth IONS has been the subject of a […] - 2025-04-23 02:50:51

Brokerages Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Target Price at $56.72

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twenty brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and […] - 2025-04-21 02:46:52

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Holdings Cut by LPL Financial LLC

LPL Financial LLC lessened its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 5.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 40,376 shares of the company’s stock after selling 2,244 shares during the period. LPL Financial LLC’s holdings in Ionis Pharmaceuticals were worth $1,412,000 as of its most recent […] - 2025-04-18 05:58:49

CIBC Private Wealth Group LLC Sells 1,300 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

CIBC Private Wealth Group LLC reduced its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 53.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,125 shares of the company’s stock after selling 1,300 shares during the quarter. CIBC […] - 2025-04-10 05:15:01

Back to Listing

Disclaimer